Hepatits C Virus (HCV) is among the leading causes of liver cirrhosis, hepatocellular carcinoma, and liver transplantation. Over the past few years major breakthroughs have been made in treatment of HCV with the advent of all-oral direct acting antiviral (DAA) regiments. Intermountain is partnering with industry sponsors to conduct clinical trials that evaluate the efficacy and safety of these new therapeutic regimens. Intermountain is also following patients who have achieved a sustained viral response (SVR) to HCV in long-term registry studies in order to assess the durability of SVR. 

Learn more about these clinical trials